This examination may be subject to debate in the face of extremely low central ghrelin levels
I hope they stay this way
Additional information DISCLOSURE/CONFLICT OF INTEREST Michael Berk declares that over the past three years, he has received compensation from Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Norvatis, Mayne Pharma and Servier
In elective TJA, where tolerance for biologic uncertainty is low, the most defensible approach remains risk minimization
A modern classification of OHSS
But that's exactly where our dedication to precise, high-purity peptides makes all the difference